bdtx-4933
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 18, 2023 (NCT05786924)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Brain Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1
- Genes, ras · Phase 1
- Histiocytic Sarcoma · Phase 1
- Histiocytosis · Phase 1
- Leukemia, Hairy Cell · Phase 1
- Lung Neoplasms · Phase 1
- Melanoma · Phase 1
- Mutation · Phase 1
- Neoplasms · Phase 1
- Proto-Oncogene Proteins B-raf · Phase 1
- ras GTPase-Activating Proteins · Phase 1
- ras Proteins · Phase 1
- Thyroid Neoplasms · Phase 1
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05786924 | Phase 1 | Apr 18, 2023 | Black Diamond Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1